Rigel Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview

Rigel Pharmaceuticals

04/11/2023 03:04

* Rigel Pharmaceuticals Inc  RIGL.OQ   RIGL.O  is expected
to show
a rise in quarterly revenue when it reports  results 
    * The South San Francisco California-based  company is
expected to
report  a 21.4% increase in revenue to $27.201 million from
$22.41 million a year ago, according to the mean estimate from 5
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Rigel
Pharmaceuticals Inc
is for a loss of 7 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $2​, above​ its last closing price
of $0.88. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.08       -0.08      -0.04     Beat    48.7
 Mar. 31 2023  -0.09       -0.10      -0.08     Beat    17.9
 Dec. 31 2022  -0.11       -0.11      0.01      Beat    108.9​
 Sep. 30 2022  -0.13       -0.13      -0.11     Beat    18.2
 ​​Jun.        -0.13       -0.12      -0.08     Beat    34.8
 30 2022                                                
 Mar. 31 2022  -0.14       -0.14      -0.16     Missed  -16.5​
 Dec. 31 2021  -0.13       -0.13      -0.13     Met     -1.8
 Sep. 30 2021  -0.09       -0.10      -0.12     Missed  -20.4
 This summary was machine generated November 4 at 03:03 GMT.  All
figures in US dollars  unless otherwise stated